Van Oene Mark sold $30K of PACB

Van Oene Mark (See Remarks) sold 26,911 shares of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) at $1.13 on 2026-08-17.

Original reporting
SEC EDGAR · Van Oene Mark
Published Aug 19, 2026, 12:17 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 12:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PACB
Neutral
medium confidence
Mentioned
$PACB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PACBNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but this specific disclosure is a small open-market sale and lacks additional fundamental catalysts in the text.

02

Market read

A newly filed insider sale can cause minor, short-term sentiment noise, but it is unlikely to drive a durable repricing without accompanying company news.

03

What to watch

The text does not confirm whether the sale was part of a 10b5-1 plan (it states 'No'), but it also provides no stated reason for the sale or any concurrent operational news.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-17

Background

The article is an SEC Form 4 insider transaction disclosure for Pacific Biosciences of California, Inc. (PACB).

Company-level read

Ticker impact

$PACBNeutralMedium confidence
Context

PACB insider Van Oene Mark sold 26,911 shares in an open-market transaction for about $30.4K, per a fresh SEC Form 4 filing.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale (not a buy), but the disclosed dollar value is relatively small and there is no 10b5-1 plan detail provided in the text.

Market effects

No sector-wide implication is disclosed; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Insider sales are often pre-planned for diversification or tax needs, so the sale may not reflect negative fundamentals.

Key entities

  • PACB

    Pacific Biosciences of California, Inc., the company whose insider transaction is disclosed.

  • Van Oene Mark

    Officer at PACB who sold 26,911 shares at $1.1300/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PACBMed

Pacific Biosciences of California Inc (PACB) (Q3 2026) Earnings Call Highlights: Revenue

Pacific Biosciences (PACB) reported Q3 2026 revenue growth of 6% YoY to $40.6M, with consumables revenue down 2% YoY. Non-GAAP gross margin fell to 36% from 42% due to higher costs. Americas and Asia Pacific revenues declined, while EMEA grew 30%. Cash burn was $32.8M, with Q4 expected to decrease. The company narrowed full-year revenue guidance to $155M-$160M and expects cash flow breakeven in 2028.

$PACBHighAI 8/10

What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call

Pacific Biosciences (PACB) reported Q3 earnings, with Revio consumables pull-through at $204,000 per system. Instrument revenue rose to $13.2M, with 15 Revio and 35 Vega systems sold. Clinical business grew over 20% YoY, now exceeding 20% of total business. Non-GAAP net loss narrowed to $32.8M, with cash at $199.4M. The company maintained its 2026 outlook and expects cash flow breakeven in 2028.

$PACBMed

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB): PacBio Announces Third Quarter 2026 Financial Results

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PacBio Announces Third Quarter 2026 Financial Results MENLO PARK, Calif., November 4, 2026 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2026. Recent Business Highlights • Delivered total revenue of $40

$PACBMed

Why PacBio (PACB) Stock Is Trading Up Today

Pacific Biosciences of California (PACB) shares rose 15% to $2.88 after EpiSign and Geneyx announced a partnership using PacBio's HiFi sequencing for rare disease analysis. The stock is up 56.5% year-to-date, reaching a 52-week high. PacBio's shares are volatile, with 87 moves over 5% in the past year.